

| <b>General information about company</b> |                          |
|--|--------------------------|
| Scrip code                               | 512299                   |
| NSE Symbol                               | STERLINBIO               |
| MSEI Symbol                              |                          |
| ISIN                                     | INE324C01038             |
| Name of the entity                       | STERLING BIOTECH LIMITED |
| Date of start of financial year          | 01-04-2018               |
| Date of end of financial year            | 31-03-2019               |
| Reporting Quarter                        | Half Yearly              |
| Date of Report                           | 30-09-2018               |
| Risk management committee                | Not Applicable           |

|  |                        |
|--|------------------------|
| <b>Annexure I</b>  |                        |
| <b>Annexure I to be submitted by listed entity on quarterly basis</b>                |                        |
| <b>I. Composition of Board of Directors</b>  |                        |
| Disclosure of notes on composition of board of directors explanatory                 | Textual Information(1) |
| Is there any change in information of board of directors compare to previous quarter | No                     |

| <b>Text Block</b>      |  |
|------------------------|--|
| Textual Information(1) | Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website)<br><br>This information pertains to number of Directorship and membership/chairmanship held in Sterling Biotech Limited only. |

| <b>Annexure 1</b>  |                        |
|--|------------------------|
| <b>II. Composition of Committees</b>   |                        |
| Disclosure of notes on composition of committees explanatory                 | Textual Information(1) |
| Is there any change in information of committees compare to previous quarter | No                     |

| <b>Annexure 1 Text Block</b> |  |
|------------------------------|--|
| Textual Information(1)       | Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website) |

| <b>Audit Committee Details</b> |            |                           |                         |                         |         |
|--------------------------------|------------|---------------------------|-------------------------|-------------------------|---------|
| Sr                             | DIN Number | Name of Committee members | Category 1 of directors | Category 2 of directors | Remarks |

| <b>Nomination and remuneration committee</b> |            |                           |                         |                         |         |
|--|------------|---------------------------|-------------------------|-------------------------|---------|
| Sr   | DIN Number | Name of Committee members | Category 1 of directors | Category 2 of directors | Remarks |

| <b>Stakeholders Relationship Committee</b> |            |                           |                         |                         |         |
|--|------------|---------------------------|-------------------------|-------------------------|---------|
| Sr   | DIN Number | Name of Committee members | Category 1 of directors | Category 2 of directors | Remarks |



| <b>Risk Management Committee</b> |            |                           |                         |                         |         |
|----------------------------------|------------|---------------------------|-------------------------|-------------------------|---------|
| Sr                               | DIN Number | Name of Committee members | Category 1 of directors | Category 2 of directors | Remarks |

| <b>Corporate Social Responsibility Committee</b> |            |                           |                         |                         |         |
|--|------------|---------------------------|-------------------------|-------------------------|---------|
| Sr   | DIN Number | Name of Committee members | Category 1 of directors | Category 2 of directors | Remarks |

| <b>Other Committee</b> |            |                           |                         |                         |                         |         |
|------------------------|------------|---------------------------|-------------------------|-------------------------|-------------------------|---------|
| Sr                     | DIN Number | Name of Committee members | Name of other committee | Category 1 of directors | Category 2 of directors | Remarks |

|  |                        |
|--|------------------------|
| <b>Annexure 1</b>  |                        |
| <b>Annexure 1</b>  |                        |
| <b>III. Meeting of Board of Directors</b>                        |                        |
| Disclosure of notes on meeting of board of directors explanatory | Textual Information(1) |

| <b>Text Block</b>      |   |
|------------------------|---|
| Textual Information(1) | <p>As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Sterling Biotech Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter.</p> |

|  |                        |
|--|------------------------|
| <b>Annexure 1</b>  |                        |
| <b>IV. Meeting of Committees</b>                         |                        |
| Disclosure of notes on meeting of committees explanatory | Textual Information(1) |

| <b>Text Block</b>      |   |
|------------------------|---|
| Textual Information(1) | <p>As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Sterling Biotech Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter.</p> |

| <b>Annexure 1</b>                    |  |                                  |  |
|--------------------------------------|--|----------------------------------|--|
| <b>V. Related Party Transactions</b> |  |                                  |  |
| Sr                                   | Subject  | Compliance status<br>(Yes/No/NA) | If status is "No" details of non-compliance may be given here. |
| 1                                    | Whether prior approval of audit committee obtained   | NA                               |  |
| 2                                    | Whether shareholder approval obtained for material RPT   | NA                               |  |
| 3                                    | Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee | NA                               |  |



| <b>Annexure 1</b>       |  |                            |
|-------------------------|--|----------------------------|
| <b>VI. Affirmations</b> |  |                            |
| Sr                      | Subject  | Compliance status (Yes/No) |
| 1                       | The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015  | No                         |
| 2                       | The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee  | No                         |
| 3                       | The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee                                   | No                         |
| 4                       | The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee                                   | No                         |
| 5                       | The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 100 listed entities) | NA                         |
| 6                       | The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.                              | Yes                        |
| 7                       | The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.                  | No                         |
| 8                       | This report and/or the report submitted in the previous quarter has been placed before Board of Directors.   | No                         |
| 9                       | Any comments/observations/advice of Board of Directors may be mentioned here:  | Textual Information(1)     |

| <b>Annexure 1</b> |                   |  |
|-------------------|-------------------|--|
| Sr                | Subject           | Compliance status  |
| 1                 | Name of signatory | Rajbhusan Dixit With Authorisation of Sundaresh Bhat Resolution Professional |
| 2                 | Designation       | Director   |

| <b>Text Block</b>      |   |
|------------------------|---|
| Textual Information(1) | <p>As already informed to Stock Exchanges Company is unable to comply with the SEBI Regulations within the prescribed time due to following reasons:</p> <p>(a) As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter. The going financial distress faced by the Company which resulted in its admission into CIRP leading to sudden change in the management;</p> <p>(b) Search Seizure operations of the Company was conducted by Directorate of Enforcement on 5th August, 2017 and due to some unforeseen circumstances, although the Notice of the 31st AGM which was scheduled to be held on 30th September, 2017 was duly sent, the AGM could not be held on the scheduled date and therefore Statutory Auditors appointment for the Financial Year 2017-18 could not be completed.</p> <p>(c) Investigation is going on in the company by Enforcement Directorate, CBI and Serious Fraud Investigation Office, therefore the employees working with Accounts, Finance and other departments are busy providing the information sought by such investigating agencies.</p> <p>(d) There is no Company Secretary, Chief Financial Officer etc. in the Company.</p> |

| <b>Annexure III</b>   |  |                                      |                               |  |
|---|--|--------------------------------------|-------------------------------|--|
| <b>Annexure III to be submitted by listed entity at the end of 6 months after end of financial year along-with second quarter report of next financial year</b> |  |                                      |                               |  |
| <b>I. Affirmations</b>  |  |                                      |                               |  |
| Sr  | Broad heading  | Regulation Number                    | Compliance status (Yes/No/NA) | If status is "No" details of non-compliance may be given here. |
| 1   | Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on website | 46(2)                                | No                            | As per note  |
| 2   | Presence of Chairperson of Audit Committee at the Annual General Meeting   | 18(1)(d)                             | No                            | As per note  |
| 3   | Presence of Chairperson of the nomination and remuneration committee at the annual general meeting   | 19(3)                                | No                            | As per note  |
| 4   | Whether "Corporate Governance Report" disclosed in Annual Report   | 34(3) read with para C of Schedule V | No                            | As per note  |
| Any other information to be provided  |  |                                      | Textual Information(1)        |  |

| <b>Text Block</b>      |   |
|------------------------|---|
| Textual Information(1) | <p>(a) As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Sterling Biotech Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter. The on-going financial distress faced by the Company which resulted in its admission into CIRP leading to sudden change in the management;</p> <p>(b) Search Seizure operations of the Company was conducted by Directorate of Enforcement on 5th August, 2017 and due to some unforeseen circumstances, although the Notice of the 31st AGM which was scheduled to be held on 30th September, 2017 was duly sent, the AGM could not be held on the scheduled date and therefore Statutory Auditors appointment for the financial year 2017-18 could not be completed.</p> <p>(c) Investigation is going on in the company by Enforcement Directorate, CBI and Serious Fraud Investigation Office, therefore the employees working with Accounts, finance and other departments are busy providing the information sought by such investigating agencies.</p> <p>(d) There is no Company Secretary, Chief Financial Officer etc. in the Company.</p> <p>The Company had applied for extension for holding 32nd Annual General Meeting of Sterling Biotech Limited for the financial year 2017-18 through e-Form GNL-1 vide SRN H09944257 dated 11/09/2018. The Registrar of Companies Mumbai had granted extension of 02 months 00 days on 18th September 2018. However, the company not being in a position to hold its 32nd Annual General Meeting (hereinafter referred to as AGM) within the extended time limit of 02 months granted by Registrar of Companies Mumbai, the Company has again applied for extension of time for holding the AGM up to 31st December 2018 through e-Form GNL-1 vide SRN H24390726 dated 27/10/2018. The status of SRN H24390726 is still pending with the Registrar of Companies Mumbai.</p> |

| <b>Annexure III</b> |                   |  |
|---------------------|-------------------|--|
| 1                   | Name of signatory | Rajbhusan Dixit With Authorisation of Sundaresh Bhat Resolution Professional |
| 2                   | Designation       | Director   |

| <b>Signatory Details</b> |  |
|--------------------------|--|
| Name of signatory        | Rajbhusan Dixit With Authorisation of Sundaresh Bhat Resolution Professional |
| Designation of person    | Director   |
| Place                    | Mumbai   |
| Date                     | 23-11-2018   |

